RxDoctor Payments Data

Brooke Sheehan

Psychiatric/Mental Health · Clackamas, ORNPI 1023154846

Payments from drug & device makers

$569in general payments, 2019–2025

Across 21 payments — averaging $27.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$177
  • E.r. Squibb & Sons, L.L.C.$125
  • Vanda Pharmaceuticals Inc.$59
  • Alkermes, Inc.$50
  • AbbVie$41
  • Sunovion Pharmaceuticals Inc.$25
  • plus $91 from 5 others

What the payments were for

  • Food & beverage$569100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$569 in reported general payments places this provider in the 70th percentile of 540 psychiatric/mental health providers in Oregon.

See all psychiatric/mental health providers in Oregon

Medicare billing

Part B allowed, 2024
$7,753
Medicare patients
14
Services billed
76

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate17$65,328
VraylarCariprazine Hcl26$35,861
TrintellixVortioxetine Hydrobromide17$10,197
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine49$2,003
Lurasidone Hcl14$1,694
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine22$1,638
Aripiprazole60$1,500
Bupropion XlBupropion Hcl38$913
Ramelteon13$824
Fluoxetine Hcl73$760
Desvenlafaxine Succinate ErDesvenlafaxine Succinate11$752
Duloxetine Hcl60$747
Olanzapine59$597
Lamotrigine82$552
Hydroxyzine Pamoate25$435

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$12$65,32817 claims
AbbVieVraylar$41$35,86126 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$19$10,19717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 540 psychiatric/mental health providers in Oregon.

Other psychiatric/mental health in Clackamas

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →